17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
In the USA, a New York jury on Thursday found that Israel-based Teva Pharmaceutical Industries’ US subsidiary contributed to a crisis of opioid abuse in the Empire State, but also placed a small portion of the blame for the epidemic on the state. 31 December 2021
The Russian Ministry of Health has officially presented a draft federal program to combat mortality from hepatitis C in Russia – a state program, adoption of which has been lobbied for by the patient community in Russia since 2011, reports The Pharma Letter’s local correspondent. 29 December 2021
Russia will simplify the procedure for imports of unregistered drugs against serious diseases starting from March of next year, according to recent statements by state authorities and local media reports. 28 December 2021
Russian drugmaker ChemRar Group says that its Avifavir (favipiravir) drug is effective against various variants of SARS-CoV-2 (coronavirus), including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp) via three complementary mechanisms, resulting in complete blockade of the viral infection. 27 December 2021
Japanese drug major Chugai Pharmaceutical today announced that it signed a joint research agreement with the Nation al Cancer Center Japan (NCC) and participated in an Asian multicenter prospective study A-TRAIN, which is led by NCC Hospital. 27 December 2021
US cancer-focussed firm Karyopharm Therapeutics has entered into an exclusive licensing agreement whereby privately-held Italian drugmaker Menarini will commercialize Nexpovio (selinexor), Karyopharm’s first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in Europe and other key global territories. 24 December 2021
A new supply agreement between the research-based biopharmaceutical industry and the State will improve patients’ access to the latest innovative medicines, according to the Irish Pharmaceutical Healthcare Association (IPHA), the representative organization for medicines innovators. 24 December 2021
A new strategic research tie-in between Aarvik Therapeutics and ArriVent Biopharma will see the firms working together to develop an undisclosed oncology-focused drug candidate. 24 December 2021
Johnson & Johnson’s pharma arm Janssen has won a positive reimbursement decision in the UK, from the country’s health technology assessor. 24 December 2021
Following an Antimicrobial Drugs Advisory Committee narrow vote of 13-10 last month in favor of the anitviral’s benefits, the US Food and Drug Administration today issued an emergency use authorization (EUA) for Merck & Co’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19). 23 December 2021
On Wednesday, the US Food and Drug Administration issued an emergency use authorization (EUA) for pharma giant Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19). 23 December 2021
Bipolar disorder is a mental disorder characterized by periods of mania and depression. While there are a high number of treatments that can effectively manage the acute mania, there is a striking lack of treatments for bipolar depression, with this unmet need set to be only partially met over the next decade. 23 December 2021
Japan’s largest drugmaker Takeda Pharmaceutical yesterday announced that it has received a Complete Response Letter (CRL) from the US Food and Drug Administration in response to its New Drug Application (NDA) for TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. 22 December 2021
Research from British online pharmacy Chemist4U has revealed some insights on the current state of prescriptions in England, including the most prescribed medicines in the country. 22 December 2021
French vaccines developer Valneva has announced positive top-line results from the lot-to-lot Phase III trial of its single-shot chikungunya vaccine candidate, VLA1553. 22 December 2021
Russia is faced with a significant delay of drug supplies to the domestic market, as producers delay signing of contracts with the local state in an attempt to make a deal with higher prices for them, according to a recent report published by the Institute of State and Municipal Administration of the Higher School of Economics (ISMU), one of Russia’s leading research institutions in the field of finance, reports The Pharma Letter’s local correspondent. 22 December 2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline, has announced that Apretude (cabotegravir), the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually-acquired HIV-1, has been approved in the USA. 21 December 2021
Topical dermatology specialist DermBiont has raised $28 million in a series A financing, at the same time as acquiring clinical-stage biotech Chromaderm. 21 December 2021
German pharma and life sciences group Merck KGaA today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine (marketed as Mavenclad for multiple sclerosis) for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). 20 December 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.